Nektar Therapeutics Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Nektar Therapeutics payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- Nektar Therapeutics payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- Nektar Therapeutics payments for repurchase of common stock for the quarter ending 2025-06-30 was $0.00.
- Nektar Therapeutics payments for repurchase of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics payments for repurchase of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Nektar Therapeutics payments for repurchase of common stock for fiscal 2024 was $3.00M.
- Nektar Therapeutics payments for repurchase of common stock for fiscal 2023 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $0.00 derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 4 quarters · filed 2026-03-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $3.00M 10-K · filed 2026-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.00M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $3.00M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-09 | $3.00M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $0.00 10-K · filed 2025-03-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |